DCMD
MCID: MCL027
MIFTS: 50

Macular Dystrophy, Dominant Cystoid (DCMD)

Categories: Eye diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Macular Dystrophy, Dominant Cystoid

MalaCards integrated aliases for Macular Dystrophy, Dominant Cystoid:

Name: Macular Dystrophy, Dominant Cystoid 56 13
Cystoid Macular Edema 12 6 15
Autosomal Dominant Cystoid Macular Edema 58 71
Cystoid Macular Dystrophy 56 58
Macular Edema, Cystoid 56 71
Dcmd 56 58
Cystoid Macular Dystrophy; Cymd 56
Familial Macular Edema 58
Macular Retinal Edema 71
Macular Edema 43
Cymd 56
Mddc 56

Characteristics:

Orphanet epidemiological data:

58
cystoid macular dystrophy
Inheritance: Autosomal dominant; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood;

OMIM:

56
Inheritance:
autosomal dominant (7p21-p15)


HPO:

31
macular dystrophy, dominant cystoid:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:4447
OMIM 56 153880
MeSH 43 D008269
NCIt 49 C34794
ICD10 via Orphanet 33 H35.5
Orphanet 58 ORPHA75381
MedGen 41 C0024440
UMLS 71 C0024440 C0271051 C0730317

Summaries for Macular Dystrophy, Dominant Cystoid

OMIM : 56 Dominant cystoid macular dystrophy (DCMD) is a progressive retinal dystrophy characterized primarily by early-onset cystoid fluid collections in the neuroretina (summary by Saksens et al., 2015). (153880)

MalaCards based summary : Macular Dystrophy, Dominant Cystoid, also known as cystoid macular edema, is related to bestrophinopathy, autosomal recessive and microvascular complications of diabetes 1, and has symptoms including edema and peau d'orange. An important gene associated with Macular Dystrophy, Dominant Cystoid is CYMD (Cystoid Macular Dystrophy), and among its related pathways/superpathways is Visual Cycle in Retinal Rods. The drugs Acetazolamide and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are edema and strabismus

Related Diseases for Macular Dystrophy, Dominant Cystoid

Diseases related to Macular Dystrophy, Dominant Cystoid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 395)
# Related Disease Score Top Affiliating Genes
1 bestrophinopathy, autosomal recessive 32.7 CRB1 BEST1 ABCA4
2 microvascular complications of diabetes 1 31.7 VEGFA SERPINF1 CXCL12
3 retinal vein occlusion 31.6 VEGFA SERPINF1 CXCL12 ACE
4 diabetic macular edema 31.4 VEGFA SERPINF1 PRKCB
5 microvascular complications of diabetes 5 31.1 VEGFA SERPINF1 PRKCB CXCL12 ACE
6 iridocyclitis 31.0 TNFRSF1B MRAP ACE
7 retinal vascular disease 30.9 VEGFA SERPINF1 ACE
8 optic disk drusen 30.9 KCNMA1 CRB1
9 macular holes 30.8 VEGFA SERPINF1 RS1 KCNMA1
10 severe nonproliferative diabetic retinopathy 30.8 VEGFA PRKCB ACE
11 intraocular pressure quantitative trait locus 30.8 VEGFA SERPINF1 PEX19
12 neuroretinitis 30.8 RCVRN MRAP ACE
13 exanthem 30.8 VEGFA TNFRSF1B ACE
14 panuveitis 30.8 VEGFA TNFRSF1B MRAP ACE
15 retinal vasculitis 30.7 TNFRSF1B MRAP ACE
16 vitreous detachment 30.6 VEGFA KCNMA1
17 posterior scleritis 30.6 MRAP ACE
18 cancer-associated retinopathy 30.6 VEGFA RCVRN
19 eales disease 30.6 VEGFA SERPINF1
20 chorioretinitis 30.5 VEGFA TNFRSF1B MRAP ACE
21 neovascular glaucoma 30.5 VEGFA RS1 PEX19
22 hypertensive retinopathy 30.4 VEGFA ACE
23 iritis 30.3 TNFRSF1B MRAP ACE
24 yemenite deaf-blind hypopigmentation syndrome 30.3 VEGFA USH2A CRB1 ABCA4
25 uveitis 30.3 TNFRSF1B SERPINF1 CAPN5
26 choroiditis 30.2 VEGFA MRAP KCNMA1 ACE
27 chorioretinal scar 30.2 VEGFA KCNMA1 CRB1
28 diabetic neuropathy 30.1 VEGFA PRKCB ACE
29 coats disease 30.1 VEGFA RS1 CRB1
30 retinal telangiectasia 30.1 VEGFA CRB1
31 scotoma 30.0 VEGFA RCVRN KCNMA1 ABCA4
32 optic papillitis 30.0 TNFRSF1B MRAP ACE
33 retinitis 29.9 USH2A PDE6A CRB1 ABCA4
34 vitreoretinal dystrophy 29.9 RS1 NR2E3
35 uveal disease 29.8 VEGFA TNFRSF1B PEX19 MRAP ACE
36 retinoschisis 1, x-linked, juvenile 29.8 RS1 NR2E3 CRB1 ABCA4
37 retinal detachment 29.7 VEGFA SERPINF1 RS1 CAPN5
38 nonsyndromic retinitis pigmentosa 29.6 USH2A MAK ABCA4
39 cone dystrophy 29.6 USH2A BEST1 ABCA4
40 usher syndrome 29.4 USH2A PDE6A CRB1 ABCA4
41 macular retinal edema 29.3 VEGFA TNFRSF1B SERPINF1 MRAP KCNMA1 CRB1
42 inherited retinal disorder 28.8 USH2A RS1 NR2E3 CRB1 BEST1 ABCA4
43 retinal disease 28.6 USH2A RS1 PDE6A NR2E3 CRB1 BEST1
44 cone-rod dystrophy 2 28.1 USH2A TNFRSF1B PDE6A NR2E3 CRB1 BEST1
45 macular degeneration, age-related, 1 27.9 VEGFA USH2A SERPINF1 RS1 RCVRN NR2E3
46 retinal degeneration 27.6 USH2A SERPINF1 RS1 RCVRN NR2E3 CRB1
47 fundus dystrophy 27.3 VEGFA USH2A RS1 RCVRN PDE6A NR2E3
48 eye disease 26.9 VEGFA USH2A SERPINF1 RS1 RCVRN PRKCB
49 retinitis pigmentosa 25.8 VEGFA USH2A SERPINF1 RS1 RCVRN PDE6A
50 vitreoretinopathy, neovascular inflammatory 11.8

Graphical network of the top 20 diseases related to Macular Dystrophy, Dominant Cystoid:



Diseases related to Macular Dystrophy, Dominant Cystoid

Symptoms & Phenotypes for Macular Dystrophy, Dominant Cystoid

Human phenotypes related to Macular Dystrophy, Dominant Cystoid:

31 (show all 6)
# Description HPO Frequency HPO Source Accession
1 edema 31 HP:0000969
2 strabismus 31 HP:0000486
3 macular dystrophy 31 HP:0007754
4 hypermetropia 31 HP:0000540
5 cystoid macular edema 31 HP:0011505
6 pericentral retinitis pigmentosa 31 HP:0007947

Symptoms via clinical synopsis from OMIM:

56
Eyes:
strabismus
cystoid macular edema
pericentral retinitis pigmentosa
whitish punctate vitreous deposits
moderate to high hyperopia
more
Radiology:
normal electroretinogram

Clinical features from OMIM:

153880

UMLS symptoms related to Macular Dystrophy, Dominant Cystoid:


edema, peau d'orange

MGI Mouse Phenotypes related to Macular Dystrophy, Dominant Cystoid:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.96 ABCA4 ACE CRB1 CXCL12 KCNMA1 PDE6A
2 nervous system MP:0003631 9.93 ABCA4 CRB1 CXCL12 KCNMA1 NR2E3 PDE6A
3 vision/eye MP:0005391 9.36 ABCA4 BEST1 CRB1 NR2E3 PDE6A RCVRN
4 pigmentation MP:0001186 9.35 ABCA4 BEST1 CRB1 RS1 SERPINF1

Drugs & Therapeutics for Macular Dystrophy, Dominant Cystoid

Drugs for Macular Dystrophy, Dominant Cystoid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 327)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4 59-66-5 1986
2
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
3
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
4
Linagliptin Approved Phase 4 668270-12-0 10096344
5
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
6
Bevacizumab Approved, Investigational Phase 4 216974-75-3
7
Homatropine Approved Phase 4 87-00-3
8
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
9
Loteprednol Approved, Experimental Phase 4 82034-46-6, 129260-79-3 444025 9865442
10
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
11
Travoprost Approved Phase 4 157283-68-6 5282226
12
Interferon beta-1b Approved Phase 4 145155-23-3
13
Interferon beta-1a Approved, Investigational Phase 4 145258-61-3 6438354
14
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
15
Bromfenac Approved Phase 4 91714-94-2 60726
16
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
17
Verteporfin Approved, Investigational Phase 4 129497-78-5
18
Ephedrine Approved Phase 4 299-42-3 9294
19
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
20
Phenylephrine Approved Phase 4 59-42-7 6041
21
Pseudoephedrine Approved Phase 4 90-82-4 7028
22
Fluprednisolone Approved Phase 4 53-34-9
23
Difluprednate Approved Phase 4 23674-86-4 443936
24
Gatifloxacin Approved, Investigational Phase 4 112811-59-3 5379
25
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
26
Polyestradiol phosphate Approved Phase 4 28014-46-2
27
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
28
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
29
Nepafenac Approved, Investigational Phase 4 78281-72-8 151075
30
Ofloxacin Approved Phase 4 82419-36-1 4583
31
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
32
Fenofibrate Approved Phase 4 49562-28-9 3339
33
Iodine Approved, Investigational Phase 4 7553-56-2 807
34
Dipivefrin Approved Phase 4 52365-63-6 3105
35
Povidone-iodine Approved Phase 4 25655-41-8
36
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
37
Povidone Approved Phase 4 9003-39-8
38
Simvastatin Approved Phase 4 79902-63-9 54454
39
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
40
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
41
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
42 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
43
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
44
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
45
Methotrexate Approved Phase 4 59-05-2, 1959-05-2 126941
46
leucovorin Approved Phase 4 58-05-9 6006 143
47
Glimepiride Approved Phase 4 93479-97-1 3476
48
Empagliflozin Approved Phase 4 864070-44-0
49
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 5538 444795
50
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354

Interventional clinical trials:

(show top 50) (show all 908)
# Name Status NCT ID Phase Drugs
1 Treatment of Cystoid Macular Edema in Patients With Retinal Degeneration Unknown status NCT00716586 Phase 4 dorzolamide
2 POSTERIOR SUB-TENON'S CAPSULE INJECTION OF BEVACIZUMAB FOR TREATMENT OF DIFFUSE DIABETIC MACULAR EDEMA Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
3 Combined Treatment of Intravitreous Bevacizumab and Triamcinolone for the Treatment or Macular Edema Secondary to Central Retinal Vein Occlusion Unknown status NCT00566761 Phase 4 bevacizumab and triamcinolone
4 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Unknown status NCT03097068 Phase 4 Lucentis
5 Phase 4 Study of Intravitreal Aflibercept Injection for Recalcitrant Central Retinal Vein Occlusion Associated Macular Edema Despite Prior Anti-Vascular Endothelial Growth Factor (VEGF) Therapy. (ARChiMEDES) Unknown status NCT01857544 Phase 4 Aflibercept
6 Phase 4 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
7 Evaluation of an Additional Therapeutic Approach to Diabetic Macular Edema by Combining Standard Therapy (Intravitreal Injection of a VEGF-inhibitor) With Micropulse Diode Laser Treatment in a Randomized, Controlled Proof of Concept Study Unknown status NCT02059772 Phase 4 ranibizumab
8 A Single Arm, Single Dose Study to Evaluate the Effect of Intravitreal Dexamethasone Implant (Ozurdex®) on Hard Exudates of Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
9 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
10 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Unknown status NCT02924987 Phase 4 Aflibercept Injection
11 To Compare the Efficacy of Monotherapy With Anti-Vascular Endothelial Growth Factor (Ranibizumab or Bevacizumab) Versus Combination Therapy With Anti-Vascular Endothelial Growth Factor and End-point-management Grid Laser Photocoagulation for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
12 The Effect of Bevacizumab on Peripheral Retinal Changes as Imaged by Wide -Field Fluorescein Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
13 Evaluation of the "Treat-and-extend" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas Unknown status NCT02522897 Phase 4 Ranibizumab
14 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
15 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
16 Randomized Trial Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With Central Retinal Vein Occlusion With a Treat and Extend Algorithm Unknown status NCT02274259 Phase 4 Aflibercept;Ranibizumab
17 Longterm Efficiency and Safety of Intravitreal Injections With Bevacizumab in Patients With Neovascularisation or Macular Edema Unknown status NCT03211741 Phase 4 Bevacizumab Injection [Avastin]
18 The Effects of Thiazolidinedione on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
19 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
20 Effects of Ranibizumab to Delay or Regression Non-proliferative Diabetic Retinopathy(NPDR) With DME Assessed by Microaneurysm Changes: A Pilot Study Unknown status NCT02834663 Phase 4 Lucentis
21 A Pilot Study to Determine if Intravitreal Injections of Pegaptanib Sodium (Macugen) Given Every 12 Weeks for a Year After an Induction Phase of Three Injections Every 6 Weeks Will Reduce the Progression of Proliferative Diabetic Retinopathy in Patients Without Significant Vitreous Hemorrhage in Comparison to Treatment With Retinal Photocoagulation Alone and After an Induction Phase Unknown status NCT01486771 Phase 4 Macugen ® (pegaptanib sodium)
22 Topical Application of ACULAR a Randomized, Vehicle Controlled Clinical Trial: Efficiency in Inhibiting Proliferative Retinopathy of Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
23 EFFECTS OF IMMEDIATE ARGON LASER PERIPHERAL IRIDOPLASTY Versus CONVENTIONAL SYSTEMIC MEDICAL THERAPY ON OPTIC NERVE HEAD STRUCTURE AND FUNCTION OF ACUTE PRIMARY ANGLE CLOSURE EYES Unknown status NCT00485238 Phase 4 Intravenous acetazolamide
24 Three Arm, Prospective, Single-blind, Randomized Study Comparing Ranibizumab Plus Green Diode Laser Versus Ranibizumab Plus Pattern Scan Laser (Pascal) Versus Ranibizumab (Monotherapy) for Proliferative Diabetic Retinopathy. Unknown status NCT02005432 Phase 4 Intravitreal Ranibizumabe;panfotocoagulation (PASCAL);panfotocoagulation (PRP) single shoot (ETDRS)
25 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Macular Edema Post Treatment. Unknown status NCT00563628 Phase 4
26 Pattern Scan Laser System vs Regular Photocoagulation System: Changes in Electroretinograms and Contrast Sensitivity Post Treatment. Unknown status NCT00563043 Phase 4
27 Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5% Completed NCT00595543 Phase 4 Bromfenac;Ketorolac;Diclofenac
28 Intraoperative Dexamethasone Implant (Ozurdex®) Improves Outcome of Cataract Surgery in Patients With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
29 A Randomized, Masked Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery. Completed NCT01542190 Phase 4 Ketorolac Tromethamine
30 The Effect of Preoperative Topical Ketorolac 0.45% on Aqueous Cytokine Levels and Macular Thickness in Diabetic and Non Diabetic Patients Undergoing Cataract Surgery Completed NCT02646072 Phase 4 Ketorolac tromethamine ophthalmic solution 0.45%
31 Bromfenac BID Plus Prednisolone Acetate BID Versus Bromfenac BID Plus Prednisolone QID for the Prevention of Cystoid Macular Edema and Retinal Thickening Completed NCT00469781 Phase 4 2. Xibrom (Bromfenac);1. Pred Forte
32 Treat and Extend Versus Dosing Every Eight Weeks With Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema (EVADE Study) Completed NCT02392364 Phase 4 Intravitreal Aflibercept Injection
33 Comparison of Ketorolac Tromethamine 0.4% and Nepafenac 0.1% for the Prevention of Cystoid Macular Edema After Phacoemulsification: Prospective Randomized Double-masked Study Completed NCT02084576 Phase 4 Nepafenac;Ketorolac
34 TAHOE: Sustained InTravitreal DexAmetHasone Implant (Ozurdex) for Uveitic Macular Edema Completed NCT01870440 Phase 4 Ozurdex Intravitreal Injection (0.7 mg)
35 Effect of Nepafenac on Post-operative Cystoid Macular Edema Following Uncomplicated Cataract Surgery Completed NCT00494494 Phase 4 Standard Care;nepafenac
36 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment Completed NCT00543296 Phase 4 0.59 mg Fluocinolone Acetonide implant
37 Impact of Different Fluidic Parameters on Development of Cystoid Macular Edema Following Phacoemulsification Completed NCT01385852 Phase 4
38 The Effects of BAK on the Blood Aqueous Barrier of Pseudophakic Patients Completed NCT01280110 Phase 4 Hydroxypropylmethylcellulose;Carboxymethylcellulose
39 Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery Completed NCT02819908 Phase 4 Imprimis Dropless;Imprimis Less Drops
40 Evaluation of ReAding Speed, Contrast Sensitivity, and Work Productivity in Working Individuals With Diabetic Macular Edema Following Treatment With Intravitreal Ranibizumab Completed NCT02107131 Phase 4 Intravitreal ranibizumab 0.3mg
41 An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema Completed NCT01297569 Phase 4 Ranibizumab
42 Prevention of Post-Photocoagulation Macular Edema by Intravitreal Bevacizumab. Completed NCT00801866 Phase 4 Bevacizumab
43 A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion Completed NCT01903720 Phase 4 dexamethasone implant
44 Randomized Clinical Trial Comparing Prophylactic Nepafenac 0.1% and Ketorolac 0.5% Versus Placebo in Preventing Postoperative Macular Edema After Uncomplicated Phacoemulsification Cataract Extraction (PNK) Completed NCT01395069 Phase 4 Nepafenac 0.1%;Ketorolac 0.5%
45 A Randomized, Parallel Group, Masked Clinical Study to Evaluate the Efficacy of Triamcinolone and Bevacizumab Through Intravitreal Injection With Individual or Simultaneous Drugs to Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
46 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy Completed NCT02472366 Phase 4 ILUVIEN
47 Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection (IAI) Treatment for Retinal Edema: PERMEATE Study Completed NCT02503540 Phase 4 Aflibercept
48 An Open-label, Multicenter, Phase IV Study of the Efficacy and Safety of Ranibizumab 0.5mg in Diabetic Patients Presenting a Visual Impairment Due to Macular Edema in Current Medical Practice Completed NCT01315275 Phase 4 Ranibizumab
49 Open-label Phase-4 Study to Examine the Change of Vision-related Quality of Life in Subjects With Diabetic Macular Edema (DME) During Treatment With Intravitreal Injections of 2 mg Aflibercept According to EU Label for the First Year of Treatment Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
50 A Single Masked, Randomized Controlled Study to Assess Efficacy of Ozurdex as Adjunct to Avastin Compared With Avastin Alone in the Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant

Search NIH Clinical Center for Macular Dystrophy, Dominant Cystoid

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Flurbiprofen
Flurbiprofen sodium

Cochrane evidence based reviews: macular edema

Genetic Tests for Macular Dystrophy, Dominant Cystoid

Anatomical Context for Macular Dystrophy, Dominant Cystoid

MalaCards organs/tissues related to Macular Dystrophy, Dominant Cystoid:

40
Eye, Endothelial, Retina, Testes, Bone, Brain, Liver

Publications for Macular Dystrophy, Dominant Cystoid

Articles related to Macular Dystrophy, Dominant Cystoid:

(show top 50) (show all 173)
# Title Authors PMID Year
1
Dominant cystoid macular dystrophy. 61 56
25267528 2015
2
Localization of the gene for dominant cystoid macular dystrophy on chromosome 7p. 56 61
8004098 1994
3
Retinal functions in dominant cystoid macular dystrophy (DCMD). 61 56
990013 1976
4
Loci for autosomal dominant retinitis pigmentosa and dominant cystoid macular dystrophy on chromosome 7p are not allelic. 56
8079997 1994
5
Dominantly inherited cystoid macular edema. 56
420475 1979
6
Dominant cystoid macular dystrophy. 56
836665 1977
7
Dominantly inherited cystoid macular edema. 56
970419 1976
8
Analysis of mass transfer behavior in membrane distillation: Mathematical modeling under various conditions. 61
31306977 2019
9
Membrane distillation as post-treatment for anaerobic fluidized bed membrane bioreactor for organic and nitrogen removal. 61
31238271 2019
10
One-step tailoring surface roughness and surface chemistry to prepare superhydrophobic polyvinylidene fluoride (PVDF) membranes for enhanced membrane distillation performances. 61
31200232 2019
11
Combined Osmotic and Membrane Distillation for Concentration of Anthocyanin from Muscadine Pomace. 61
31313316 2019
12
Application of direct contact membrane distillation for saline dairy effluent treatment: performance and fouling analysis. 61
29948689 2019
13
Slippery for scaling resistance in membrane distillation: A novel porous micropillared superhydrophobic surface. 61
30844676 2019
14
Triple-Layer Nanofiber Membranes for Treating High Salinity Brines Using Direct Contact Membrane Distillation. 61
31064093 2019
15
Performance Comparison between Polyvinylidene Fluoride and Polytetrafluoroethylene Hollow Fiber Membranes for Direct Contact Membrane Distillation. 61
30978973 2019
16
Effective treatment of reverse osmosis concentrate from incineration leachate using direct contact membrane distillation coupled with a NaOH/PAM pre-treatment process. 61
30583212 2019
17
Optimization of membrane modification using SiO2 for robust anti-fouling performance with calcium-humic acid feed in membrane distillation. 61
30623884 2019
18
Influence of Hydraulic Pressure on Performance Deterioration of Direct Contact Membrane Distillation (DCMD) Process. 61
30845780 2019
19
Acid mine drainage treatment by integrated submerged membrane distillation-sorption system. 61
30609501 2019
20
Experimental Evaluation of the Thermal Polarization in Direct Contact Membrane Distillation Using Electrospun Nanofiber Membranes Doped With Molecular Probes. 61
30759729 2019
21
Surface Modification of PVDF Membranes for Treating Produced Waters by Direct Contact Membrane Distillation. 61
30813570 2019
22
Evaluating the potential of superhydrophobic nanoporous alumina membranes for direct contact membrane distillation. 61
30199828 2019
23
Influence of dye class on the comparison of direct contact and vacuum membrane distillation applied to remediation of dyeing wastewater. 61
31361190 2019
24
Dye Synthetic Solution Treatment by Direct Contact Membrane Distillation using Commercial Membranes. 61
30569840 2018
25
Three-dimensional shape and velocity changes affect responses of a locust visual interneuron to approaching objects. 61
30341087 2018
26
Fabrication of Janus Membranes for Desalination of Oil-Contaminated Saline Water. 61
30511847 2018
27
Fluorographite-co-polydimethylsiloxane coated polyvinylidene-fluoride membrane for desalination of highly saline water with humic acid in direct contact membrane distillation. 61
30075397 2018
28
Application of membrane distillation for the treatment of anaerobic membrane bioreactor effluent: An especial attention to the operating conditions. 61
29890491 2018
29
Performance evaluation of hybrid OMBR-MD using organic and inorganic draw solutions. 61
30252655 2018
30
Membrane distillation for industrial wastewater treatment: Studying the effects of membrane parameters on the wetting performance. 61
29803107 2018
31
Stable Superhydrophobic Ceramic-Based Carbon Nanotube Composite Desalination Membranes. 61
30085681 2018
32
Direct contact membrane distillation applied to saline wastewater: parameter optimization. 61
30065134 2018
33
Mixed Matrix Polytetrafluoroethylene/Polysulfone Electrospun Nanofibrous Membranes for Water Desalination by Membrane Distillation. 61
29924587 2018
34
Removal of selected pesticides from groundwater by membrane distillation. 61
28424956 2018
35
Fouling development in direct contact membrane distillation: Non-invasive monitoring and destructive analysis. 61
29304446 2018
36
Comparison of colloidal silica involved fouling behavior in three membrane distillation configurations using PTFE membrane. 61
29248804 2018
37
Performance and fouling mechanism of direct contact membrane distillation (DCMD) treating fermentation wastewater with high organic concentrations. 61
29548396 2018
38
Performance and Fouling Study of Asymmetric PVDF Membrane Applied in the Concentration of Organic Fertilizer by Direct Contact Membrane Distillation (DCMD). 61
29462942 2018
39
Modeling the Concentration of Volatile and Semivolatile Contaminants in Direct Contact Membrane Distillation (DCMD) Product Water. 61
29111695 2017
40
Direct contact membrane distillation for textile wastewater treatment: a state of the art review. 61
29168697 2017
41
Membrane Distillation of Meat Industry Effluent with Hydrophilic Polyurethane Coated Polytetrafluoroethylene Membranes. 61
28961203 2017
42
Engineering the Re-Entrant Hierarchy and Surface Energy of PDMS-PVDF Membrane for Membrane Distillation Using a Facile and Benign Microsphere Coating. 61
28753303 2017
43
Food deprivation and prior anoxic coma have opposite effects on the activity of a visual interneuron in the locust. 61
28237581 2017
44
A sublethal dose of a neonicotinoid insecticide disrupts visual processing and collision avoidance behaviour in Locusta migratoria. 61
28428563 2017
45
Simplified bionic solutions: a simple bio-inspired vehicle collision detection system. 61
28091394 2017
46
Grasshopper DCMD: An Undergraduate Electrophysiology Lab for Investigating Single-Unit Responses to Behaviorally-Relevant Stimuli. 61
28690439 2017
47
A novel multi-stage direct contact membrane distillation module: Design, experimental and theoretical approaches. 61
27837732 2016
48
Preparation of Interconnected Biomimetic Poly(vinylidene fluoride-co-chlorotrifluoroethylene) Hydrophobic Membrane by Tuning the Two-Stage Phase Inversion Process. 61
27933838 2016
49
A hybrid process combining homogeneous catalytic ozonation and membrane distillation for wastewater treatment. 61
27372262 2016
50
Octopamine stabilizes conduction reliability of an unmyelinated axon during hypoxic stress. 61
27281750 2016

Variations for Macular Dystrophy, Dominant Cystoid

ClinVar genetic disease variations for Macular Dystrophy, Dominant Cystoid:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EYS NM_001142800.2(EYS):c.8519A>G (p.Glu2840Gly)SNV Uncertain significance 523415 rs1554163965 6:64431408-64431408 6:63721512-63721512

Expression for Macular Dystrophy, Dominant Cystoid

Search GEO for disease gene expression data for Macular Dystrophy, Dominant Cystoid.

Pathways for Macular Dystrophy, Dominant Cystoid

Pathways related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.77 RCVRN PRKCB PDE6A

GO Terms for Macular Dystrophy, Dominant Cystoid

Cellular components related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 photoreceptor outer segment GO:0001750 9.13 RCVRN MAK ABCA4
2 photoreceptor inner segment GO:0001917 8.92 USH2A RCVRN MAK CRB1

Biological processes related to Macular Dystrophy, Dominant Cystoid according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 kidney development GO:0001822 9.65 VEGFA SERPINF1 ACE
2 retina development in camera-type eye GO:0060041 9.61 SERPINF1 PDE6A NR2E3
3 photoreceptor cell maintenance GO:0045494 9.5 USH2A MAK ABCA4
4 response to stimulus GO:0050896 9.5 USH2A RS1 RCVRN PDE6A NR2E3 BEST1
5 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.49 VEGFA PRKCB
6 induction of positive chemotaxis GO:0050930 9.46 VEGFA CXCL12
7 regulation of calcium ion transport GO:0051924 9.43 RCVRN CXCL12 BEST1
8 positive regulation of axon extension involved in axon guidance GO:0048842 9.4 VEGFA CXCL12
9 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.37 VEGFA ACE
10 eye photoreceptor cell development GO:0042462 9.33 VEGFA NR2E3 CRB1
11 visual perception GO:0007601 9.17 USH2A RS1 RCVRN PDE6A NR2E3 BEST1

Sources for Macular Dystrophy, Dominant Cystoid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....